Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-03
2006-01-03
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S885000, C530S300000, C530S350000, C530S330000, C530S331000
Reexamination Certificate
active
06982246
ABSTRACT:
Novel oligopeptides comprising a sequence associated with HLA-B α1domain, but comprising a tyrosine-tyrosine-tryptophan triad are provided for use in inhibiting cytotoxic activity of CTLs and natural killer cells. By combining the subject compositions with mixtures of cells comprising the cytotoxic cells and cells which would otherwise activate the cytotoxic cells, lysis of the target cells can be substantially inhibited. the oligopeptides may be joined to a wide variety of other groups or compounds for varying the activity of the subject compositions. The subject compositions may be administered by any convenient means to a host to inhibit CTL and NK attack on tissue, particularly involved with xenogeneic or allogeneic transplants.
REFERENCES:
patent: 5723128 (1998-03-01), Clayberger et al.
patent: WO 93/08817 (1993-05-01), None
patent: WO 93/17699 (1993-09-01), None
patent: WO 94/02162 (1994-02-01), None
patent: WO 95/132881/ (1995-05-01), None
patent: WO 88/05784 (1998-08-01), None
Mikayama et al. PNAS, 1993. 90: 10056-10060.
Burgess et al J Cell Biol. 111:2129-2138, 1990.
Lazar et al. Mol Cell Biol. 8:1247-1252, 1988.
Bowie et al. Science, 247:1306-1310, 1990, p. 1306.
Ngo et al, The Protein Folding Problem and Tertiary Structure Predicition, 1994. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Buelow et al., “Immunomodulation by soluble HLA class 1, ” Transplantation, 59(5):649-654 (1995.
Bhorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. “Structure of the human class I histocompatibility antgen, HLA-A2,” Nature. Oct. 8-14, 1987;329(6139):506-12.
Dal Porto J, Johansen TE, Catipovic B, Parfiit DJ, Tuveson D, Gether U, Kozlowski S, Fearon DT, Schneck JP. “A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations,” Proc Natl Acad Sci U S A. Jul. 15, 1993;90(14):6671-5.
Wood, W. B. et al. (Eds.) Biochemistry Benjamin/Cummings Publishing Co., Menlo Park, CA, pp. 1415 (1981).
Belyavskyi Michail A.
Dorsey & Whitney LLP
Lorenz Todd A.
SangStat Medical Corporation
LandOfFree
Cytomodulating peptide for inhibiting lymphocyte activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytomodulating peptide for inhibiting lymphocyte activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytomodulating peptide for inhibiting lymphocyte activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3548625